MicroHealth is dedicated to developing digital therapeutics aimed at addressing unmet medical needs in hematology and oncology. The company builds networks of doctors and patients to track, predict, and prevent diseases. By validating the safety and efficacy of their interventions through pivotal clinical studies, MicroHealth seeks regulatory clearance for their software as a medical device (SaMD) and aims to commercialize their products as prescription digital therapeutics (DTx).
MicroHealth has established itself as a leader in digital hematology, particularly in the management of hemophilia. Their network encompasses a significant percentage of prophylaxis patients and hemophilia treatment centers (HTCs) in the US. By leveraging real-world data and predictive AI models, MicroHealth empowers users with timely information to better manage their conditions, thereby improving patient outcomes and setting a new standard in digital hematology care.
